Joel Lexchin
York University
H-index: 53
North America-Canada
Top articles of Joel Lexchin
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
RE: Pharmaceutical industry spending on R&D in Canada | Joel Lexchin | 2024/3/18 | |
Raising the bar for disclosure of industry payments to doctors | bmj | David B Menkes Barbara Mintzes Nikki Macdonald Joel Lexchin | 2024/2/29 |
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study | Journal of General Internal Medicine | Joel Lexchin | 2024/2/7 |
Article History | Lotte De Schrijver Adina Cismaru Inescu Bastien Hahaut Christophe Vandeviver Laurent Nisen | 2021 | |
Profits First, Health Second: the Pharmaceutical Industry and the Global South; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical … | International Journal of Health Policy and Management | Joel Lexchin | 2024/4/20 |
Therapeutic Benefit From New Drugs From Pharmaceutical Companies | JAMA Internal Medicine | Joel Lexchin | 2024/1/1 |
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? | International Journal of Social Determinants of Health and Health Services | Brigitte Tenni Joel Lexchin Sovath Phin Deborah Gleeson | 2024/4/2 |
Cost-of-living challenges highlight urgency for clinicians to prescribe affordable medications | Canadian Family Physician | Iris Gorfinkel Joel R Lexchin | 2023/9 |
The World Health Organization’s guidelines for medicine donations: How are they working and their future | APHA 2023 Annual Meeting and Expo | Hannah Permaul Flores Joel Lexchin | 2023/11/15 |
RE: Optimizing medications in older adults with cognitive impairment | Joel Lexchin | 2023/12/19 | |
Protocol: For health or for profit? Understanding how private financing and for-profit delivery operate within Canadian healthcare (4H| 4P): protocol for a multimethod … | BMJ Open | Lindsay Hedden Sarah Spencer Sara Allin Damien Contandriopoulos Frank Gavin | 2023 |
Prediction of therapeutic value of new drugs approved by health Canada from 2011− 2020: A cross-sectional study | JRSM open | Joel Lexchin | 2023/5 |
Improving access to medicines and beyond: the national volume-based procurement policy in China | Zheng Zhu Quan Wang Qiang Sun Joel Lexchin Li Yang | 2023/7/1 | |
Les défis du coût de la vie soulignent l’urgence pour les médecins de prescrire des médicaments abordables | Canadian Family Physician | Iris Gorfinkel Joel R Lexchin | 2023/9/1 |
RE: New CMAJ policy on competing interests in guidelines | Joel Lexchin | 2023/11/7 | |
Semaglutide: a new drug for the treatment of obesity | Joel Lexchin Barbara Mintzes | 2023/12/1 | |
Complaints about violations of voluntary and pharmaceutical industry-run medicine promotion codes in Canada | International Journal of Social Determinants of Health and Health Services | Joel Lexchin | 2023/3/20 |
EE UU y Canadá | Boletín Fármacos | Joel Lexchin | 2023 |
Lessons from India and Thailand for Cambodia's future implementation of the TRIPS Agreement for pharmaceutical patents | The Journal of World Intellectual Property | Brigitte Tenni Joel Lexchin Sovath Phin Chalermsak Kittitrakul Deborah Gleeson | 2023/7 |
Medicine donations: a review of policies and practices | Hannah Permaul Flores Jillian C Kohler Deirdre Dimancesco Anna Wong Joel Lexchin | 2023/9/1 |
